![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ELF3 |
Gene summary for ELF3 |
![]() |
Gene information | Species | Human | Gene symbol | ELF3 | Gene ID | 1999 |
Gene name | E74 like ETS transcription factor 3 | |
Gene Alias | EPR-1 | |
Cytomap | 1q32.1 | |
Gene Type | protein-coding | GO ID | GO:0001701 | UniProtAcc | A0A024R974 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1999 | ELF3 | GSM4909281 | Human | Breast | IDC | 2.78e-05 | -3.36e-01 | 0.21 |
1999 | ELF3 | GSM4909282 | Human | Breast | IDC | 2.97e-05 | 2.69e-01 | -0.0288 |
1999 | ELF3 | GSM4909286 | Human | Breast | IDC | 1.26e-03 | 1.29e-01 | 0.1081 |
1999 | ELF3 | GSM4909288 | Human | Breast | IDC | 1.35e-05 | -6.26e-01 | 0.0988 |
1999 | ELF3 | GSM4909290 | Human | Breast | IDC | 3.82e-14 | -6.31e-01 | 0.2096 |
1999 | ELF3 | GSM4909294 | Human | Breast | IDC | 2.45e-15 | -5.26e-01 | 0.2022 |
1999 | ELF3 | GSM4909296 | Human | Breast | IDC | 1.08e-03 | -1.67e-01 | 0.1524 |
1999 | ELF3 | GSM4909297 | Human | Breast | IDC | 2.19e-09 | -2.48e-01 | 0.1517 |
1999 | ELF3 | GSM4909299 | Human | Breast | IDC | 3.80e-05 | 2.76e-01 | 0.035 |
1999 | ELF3 | GSM4909300 | Human | Breast | IDC | 4.72e-04 | 4.84e-01 | 0.0334 |
1999 | ELF3 | GSM4909301 | Human | Breast | IDC | 6.50e-24 | 4.77e-01 | 0.1577 |
1999 | ELF3 | GSM4909304 | Human | Breast | IDC | 6.89e-13 | -5.49e-01 | 0.1636 |
1999 | ELF3 | GSM4909306 | Human | Breast | IDC | 1.43e-13 | 4.44e-01 | 0.1564 |
1999 | ELF3 | GSM4909311 | Human | Breast | IDC | 4.11e-37 | -6.21e-01 | 0.1534 |
1999 | ELF3 | GSM4909312 | Human | Breast | IDC | 1.33e-03 | -2.43e-01 | 0.1552 |
1999 | ELF3 | GSM4909313 | Human | Breast | IDC | 1.18e-13 | 5.23e-01 | 0.0391 |
1999 | ELF3 | GSM4909315 | Human | Breast | IDC | 5.76e-26 | -7.68e-01 | 0.21 |
1999 | ELF3 | GSM4909316 | Human | Breast | IDC | 6.89e-13 | -8.66e-01 | 0.21 |
1999 | ELF3 | GSM4909319 | Human | Breast | IDC | 2.49e-45 | -6.45e-02 | 0.1563 |
1999 | ELF3 | GSM4909321 | Human | Breast | IDC | 1.26e-48 | 6.88e-01 | 0.1559 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004873218 | Prostate | BPH | gland development | 122/3107 | 436/18723 | 1.13e-09 | 5.01e-08 | 122 |
GO:000170110 | Prostate | BPH | in utero embryonic development | 104/3107 | 367/18723 | 9.17e-09 | 3.10e-07 | 104 |
GO:002261210 | Prostate | BPH | gland morphogenesis | 42/3107 | 118/18723 | 4.36e-07 | 8.87e-06 | 42 |
GO:00430621 | Prostate | BPH | extracellular structure organization | 67/3107 | 302/18723 | 6.67e-03 | 3.00e-02 | 67 |
GO:00018242 | Prostate | BPH | blastocyst development | 28/3107 | 106/18723 | 6.86e-03 | 3.08e-02 | 28 |
GO:00308799 | Prostate | BPH | mammary gland development | 34/3107 | 137/18723 | 8.77e-03 | 3.75e-02 | 34 |
GO:00301981 | Prostate | BPH | extracellular matrix organization | 66/3107 | 301/18723 | 9.20e-03 | 3.92e-02 | 66 |
GO:00452291 | Prostate | BPH | external encapsulating structure organization | 66/3107 | 304/18723 | 1.15e-02 | 4.66e-02 | 66 |
GO:004873219 | Prostate | Tumor | gland development | 132/3246 | 436/18723 | 1.40e-11 | 1.04e-09 | 132 |
GO:002261213 | Prostate | Tumor | gland morphogenesis | 47/3246 | 118/18723 | 6.18e-09 | 2.42e-07 | 47 |
GO:000170115 | Prostate | Tumor | in utero embryonic development | 106/3246 | 367/18723 | 2.37e-08 | 8.09e-07 | 106 |
GO:003087913 | Prostate | Tumor | mammary gland development | 38/3246 | 137/18723 | 1.60e-03 | 9.71e-03 | 38 |
GO:00604434 | Prostate | Tumor | mammary gland morphogenesis | 14/3246 | 43/18723 | 1.12e-02 | 4.60e-02 | 14 |
GO:004873226 | Skin | AK | gland development | 93/1910 | 436/18723 | 3.24e-12 | 7.10e-10 | 93 |
GO:000170120 | Skin | AK | in utero embryonic development | 75/1910 | 367/18723 | 3.09e-09 | 2.62e-07 | 75 |
GO:002261217 | Skin | AK | gland morphogenesis | 32/1910 | 118/18723 | 1.68e-07 | 7.09e-06 | 32 |
GO:003087915 | Skin | AK | mammary gland development | 31/1910 | 137/18723 | 1.60e-05 | 3.09e-04 | 31 |
GO:00018245 | Skin | AK | blastocyst development | 24/1910 | 106/18723 | 1.38e-04 | 1.69e-03 | 24 |
GO:00604436 | Skin | AK | mammary gland morphogenesis | 12/1910 | 43/18723 | 9.25e-04 | 7.53e-03 | 12 |
GO:00487714 | Skin | AK | tissue remodeling | 29/1910 | 175/18723 | 5.97e-03 | 3.23e-02 | 29 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
ELF3 | MEGA | Liver | Healthy | FXYD2,LGALS4,AC090498.1, etc. | 3.80e-02 | ![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ELF3 | SNV | Missense_Mutation | c.22N>G | p.Ser8Gly | p.S8G | P78545 | protein_coding | tolerated(0.15) | benign(0.034) | TCGA-E2-A15R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
ELF3 | SNV | Missense_Mutation | rs750329636 | c.281N>A | p.Arg94Gln | p.R94Q | P78545 | protein_coding | tolerated(0.31) | benign(0.013) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
ELF3 | SNV | Missense_Mutation | c.463G>A | p.Asp155Asn | p.D155N | P78545 | protein_coding | tolerated(0.14) | benign(0.244) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
ELF3 | SNV | Missense_Mutation | c.752G>A | p.Arg251Gln | p.R251Q | P78545 | protein_coding | tolerated(0.06) | probably_damaging(0.994) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
ELF3 | SNV | Missense_Mutation | rs745722163 | c.203N>T | p.Ser68Leu | p.S68L | P78545 | protein_coding | deleterious(0) | possibly_damaging(0.503) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ELF3 | SNV | Missense_Mutation | c.1087N>A | p.Glu363Lys | p.E363K | P78545 | protein_coding | tolerated(0.17) | benign(0.306) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
ELF3 | SNV | Missense_Mutation | c.198C>G | p.Phe66Leu | p.F66L | P78545 | protein_coding | tolerated(0.66) | benign(0) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
ELF3 | SNV | Missense_Mutation | c.163N>A | p.Glu55Lys | p.E55K | P78545 | protein_coding | tolerated(0.25) | benign(0.197) | TCGA-4N-A93T-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | SD | |
ELF3 | SNV | Missense_Mutation | novel | c.473N>G | p.Pro158Arg | p.P158R | P78545 | protein_coding | tolerated(0.07) | benign(0.157) | TCGA-AA-A01K-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folinic | CR |
ELF3 | SNV | Missense_Mutation | novel | c.440G>T | p.Gly147Val | p.G147V | P78545 | protein_coding | tolerated(0.41) | benign(0.034) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |